In the last trading session, 0.16 million shares of the Xilio Therapeutics Inc (NASDAQ:XLO) were traded, and its beta was -0.21. Most recently the company’s share price was $1.14, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $52.16M. XLO currently trades at a discount to its 52-week high of $1.93, offering almost -69.3% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 56.14% since then. We note from Xilio Therapeutics Inc’s average daily trading volume that its 10-day average is 0.36 million shares, with the 3-month average coming to 523.61K.
Xilio Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended XLO as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.2167 on recent trading dayincreased the stock’s daily price by 6.3%. The company’s shares are currently up 19.37% year-to-date, but still up 3.64% over the last five days. On the other hand, Xilio Therapeutics Inc (NASDAQ:XLO) is 19.01% up in the 30-day period. We can see from the shorts that 0.38 million shares have been sold at a short interest cover period of 0.46 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 83.71% from its current value. Analyst projections state that XLO is forecast to be at a low of $7 and a high of $7.
Xilio Therapeutics Inc (XLO) estimates and forecasts
Xilio Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 23.28 percent over the past six months and at a 58.99% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.91%.
XLO Dividends
Xilio Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 39.06% of Xilio Therapeutics Inc shares, and 28.36% of them are in the hands of institutional investors. The stock currently has a share float of 46.54%. Xilio Therapeutics Inc stock is held by 34.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 13.5618% of the shares, which is about 3.79 million shares worth $3.59 million.
ROCK SPRINGS CAPITAL MANAGEMENT LP, with 10.7595% or 3.0 million shares worth $2.85 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
